PureTech to use milk-derived exosomes to deliver Roche’s antisense therapies
In a multi-year deal, PureTech Health PLC will use its milk-derived exosome platform to develop oral delivery formulations of Roche’s antisense oligonucleotides and locked nucleic acid oligonucleotides. Roche retains an option to commercialize resulting products.
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.